| Target Price | $51.00 |
| Price | $44.22 |
| Potential | 15.33% |
| Number of Estimates | 18 |
| 18 Analysts have issued a price target Exelon 2026 . The average Exelon target price is $51.00. This is 15.33% higher than the current stock price. The highest price target is $59.85 35.35% , the lowest is $42.42 4.07% . | |
| A rating was issued by 24 analysts: 11 Analysts recommend Exelon to buy, 11 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Exelon stock has an average upside potential 2026 of 15.33% . Most analysts recommend the Exelon stock at Buy or hold. |
19 Analysts have issued a sales forecast Exelon 2025 . The average Exelon sales estimate is $24.4b . This is 0.38% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $26.2b 7.76% , the lowest is $22.9b 5.63% .
This results in the following potential growth metrics:
| 2024 | $23.0b | 5.99% |
|---|---|---|
| 2025 | $24.4b | 6.00% |
| 2026 | $25.2b | 3.25% |
| 2027 | $25.9b | 2.73% |
| 2028 | $27.0b | 4.10% |
| 2029 | $27.4b | 1.80% |
| 2030 | $27.2b | 0.87% |
17 Analysts have issued an Exelon EBITDA forecast 2025. The average Exelon EBITDA estimate is $8.8b . This is 1.14% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $9.4b 8.27% , the lowest is $8.2b 5.43% .
This results in the following potential growth metrics and future EBITDA Margins:
| 2024 | $7.9b | 5.08% |
|---|---|---|
| 2025 | $8.8b | 11.24% |
| 2026 | $9.5b | 8.20% |
| 2027 | $10.3b | 7.83% |
| 2028 | $10.9b | 6.68% |
| 2029 | $11.3b | 3.11% |
| 2024 | 34.31% | 0.86% |
|---|---|---|
| 2025 | 36.01% | 4.95% |
| 2026 | 37.73% | 4.78% |
| 2027 | 39.61% | 4.98% |
| 2028 | 40.59% | 2.47% |
| 2029 | 41.11% | 1.28% |
21 Exelon Analysts have issued a net profit forecast 2025. The average Exelon net profit estimate is $2.8b . This is 2.00% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.9b 4.13% , the lowest is $2.6b 6.32% .
This results in the following potential growth metrics and future Net Margins:
| 2024 | $2.5b | 5.67% |
|---|---|---|
| 2025 | $2.8b | 12.38% |
| 2026 | $2.9b | 5.03% |
| 2027 | $3.1b | 6.50% |
| 2028 | $3.3b | 6.43% |
| 2029 | $3.5b | 5.64% |
| 2030 | $3.5b | 1.81% |
| 2024 | 10.68% | 0.30% |
|---|---|---|
| 2025 | 11.33% | 6.06% |
| 2026 | 11.52% | 1.68% |
| 2027 | 11.94% | 3.65% |
| 2028 | 12.21% | 2.26% |
| 2029 | 12.67% | 3.77% |
| 2030 | 13.01% | 2.68% |
21 Analysts have issued a Exelon forecast for earnings per share. The average Exelon EPS is $2.74 . This is 1.79% lower than earnings per share in the financial year 2024. The highest EPS forecast is $2.91 4.30% , the lowest is $2.62 6.09% .
This results in the following potential growth metrics and future valuations:
| 2024 | $2.45 | 4.70% |
|---|---|---|
| 2025 | $2.74 | 11.84% |
| 2026 | $2.87 | 4.74% |
| 2027 | $3.06 | 6.62% |
| 2028 | $3.26 | 6.54% |
| 2029 | $3.44 | 5.52% |
| 2030 | $3.50 | 1.74% |
| Current | 15.85 | 4.03% |
|---|---|---|
| 2025 | 16.16 | 1.96% |
| 2026 | 15.38 | 4.83% |
| 2027 | 14.44 | 6.11% |
| 2028 | 13.57 | 6.02% |
| 2029 | 12.85 | 5.31% |
| 2030 | 12.62 | 1.79% |
Based on analysts' sales estimates for 2025, the Exelon stock is valued at an EV/Sales of 3.81 and an P/S ratio of 1.83 .
This results in the following potential growth metrics and future valuations:
| Current | 3.83 | 6.39% |
|---|---|---|
| 2025 | 3.81 | 0.46% |
| 2026 | 3.69 | 3.15% |
| 2027 | 3.59 | 2.66% |
| 2028 | 3.45 | 3.93% |
| 2029 | 3.39 | 1.77% |
| 2030 | 3.42 | 0.88% |
| Current | 1.84 | 13.68% |
|---|---|---|
| 2025 | 1.83 | 0.38% |
| 2026 | 1.77 | 3.15% |
| 2027 | 1.73 | 2.66% |
| 2028 | 1.66 | 3.94% |
| 2029 | 1.63 | 1.77% |
| 2030 | 1.64 | 0.88% |
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Neutral
➜
Neutral
|
Unchanged | Dec 12 2025 |
| Wells Fargo |
➜
Overweight
|
Initiated | Oct 28 2025 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 22 2025 |
| Jefferies |
Buy
➜
Buy
|
Unchanged | Oct 15 2025 |
| Keybanc |
Underweight
➜
Underweight
|
Unchanged | Oct 15 2025 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Oct 14 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Oct 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
JP Morgan:
Neutral
➜
Neutral
|
Dec 12 2025 |
|
Initiated
Wells Fargo:
➜
Overweight
|
Oct 28 2025 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Oct 22 2025 |
|
Unchanged
Jefferies:
Buy
➜
Buy
|
Oct 15 2025 |
|
Unchanged
Keybanc:
Underweight
➜
Underweight
|
Oct 15 2025 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Oct 14 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Oct 10 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


